PMID- 24717951
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20220310
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 28
IP  - 2
DP  - 2014 Mar-Apr
TI  - Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with 
      allergic rhinitis.
PG  - 131-9
LID - 10.2500/ajra.2014.28.4006 [doi]
AB  - BACKGROUND: Sublingual immunotherapy (SLIT) is recommended for allergic diseases. 
      However, clinical studies containing evidence-based data of this treatment in 
      young children, which is rarely reported in the literature, are needed. This 
      study was designed to assess the efficacy and safety of SLIT in children, 
      including very young children. METHODS: Two hundred sixty-four children aged 3-13 
      years old (133 children, 3-5 years old) with Dermatophagoides farinae-induced 
      allergic rhinitis with or without asthma treated by standard pharmacotherapy had 
      randomly received either SLIT (SLIT group) or no SLIT (control group) for 12 
      months. Symptoms, medications, visual analog scale (VAS) and presence of adverse 
      events (AEs) were assessed at monthly visits. Skin-prick test and 
      Dermatophagoides farinae-specific IgE and IgG4 were measured before and after 
      treatment. RESULTS: Both treatments were effective in the global clinical scores 
      during the first seven visits when compared with baseline (all, p < 0.01), and 
      SLIT showed lower symptoms scores and VAS scores throughout this period (all, p < 
      0.01). These improvements continued until the later visits only in the SLIT 
      group. Also, the asthma medication consumption was decreased by SLIT treatment 
      only at the end of study (p < 0.01). The specific IgG4 was significantly 
      increased after SLIT treatment when compared with the control group, but no 
      significant change of specific IgE was observed in either groups. In the SLIT 
      group, there was no significant difference between children less than or more 
      than 5 years old in terms of clinical efficacy, onset of action, immunologic 
      parameters, and safety. No severe systemic AEs were reported. CONCLUSION: SLIT is 
      effective and well-tolerated in children with allergic rhinitis 3-13 years old.
FAU - Shao, Jie
AU  - Shao J
AD  - Department of Pediatrics, Ruijin Hospital, Shanghai Jiao Tong University School 
      of Medicine, Shanghai, China.
FAU - Cui, Yu-xia
AU  - Cui YX
FAU - Zheng, Yu-fei
AU  - Zheng YF
FAU - Peng, Han-fen
AU  - Peng HF
FAU - Zheng, Zhu-li
AU  - Zheng ZL
FAU - Chen, Jing-ya
AU  - Chen JY
FAU - Li, Qin
AU  - Li Q
FAU - Cao, Lan-fang
AU  - Cao LF
LA  - eng
PT  - Address
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Immunoglobulin G)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Administration, Sublingual
MH  - Adolescent
MH  - Animals
MH  - Antigens, Dermatophagoides/*administration & dosage/adverse effects
MH  - Asthma/complications/immunology/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Dermatophagoides farinae/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Rhinitis, Allergic/complications/immunology/*therapy
MH  - Skin Tests
MH  - Treatment Outcome
EDAT- 2014/04/11 06:00
MHDA- 2015/04/17 06:00
CRDT- 2014/04/11 06:00
PHST- 2014/04/11 06:00 [entrez]
PHST- 2014/04/11 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
AID - 10.2500/ajra.2014.28.4006 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2014 Mar-Apr;28(2):131-9. doi: 10.2500/ajra.2014.28.4006.